创新药获孤儿药认定,仿制药注册捷报频传!国内药企在美国市场多点开花

制药网
Oct 21

近日,多家国内药企相继发布在美国市场的药物研发及注册进展,涵盖创新型抗体偶联药物(ADC)与仿制药领域,不仅体现出国内药企在研发实力上的持续提升,更凸显其加速拓展国际市场的战略布局,为我国医药产业国际化发展注入新动力。其中,10月20日,复宏汉霖宣布,公司创新型程序性死亡-配体1(PD-L1)抗体偶联药物(ADC)注射用HLX43已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10